{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4720","upperLimit":"5.5368","value":"1.6166"},{"groupId":"OG001","lowerLimit":"5.1453","upperLimit":"16.5491","value":"9.2277"},{"groupId":"OG002","lowerLimit":"11.0030","upperLimit":"17.5416","value":"13.8928"},{"groupId":"OG003","lowerLimit":"13.3380","upperLimit":"39.3374","value":"22.9060"},{"groupId":"OG004","lowerLimit":"16.9024","upperLimit":"39.3058","value":"25.7752"},{"groupId":"OG005","lowerLimit":"25.7883","upperLimit":"43.6945","value":"33.5680"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"49"}],"units":"Participants"}],"description":"Certolizumab Pegol (CZP) plasma concentration level was measured in micrograms per milliliter (ug/ml).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received CZP 50 milligrams (mg) sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q4W (maintenance dose) from Week 8 onwards.","id":"OG000","title":"Reduced CZP Dose -Weight Group: 10 - <20 kg"},{"description":"Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG001","title":"Reduced CZP Dose - Weight Group: 20 - <40 kg"},{"description":"Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG002","title":"Reduced CZP Dose - Weight Group: >=40 kg"},{"description":"Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG003","title":"Original CZP Dose - Weight Group: 10 - <20 kg"},{"description":"Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG004","title":"Original CZP Dose - Weight Group: 20 - <40 kg"},{"description":"Participants received CZP 400 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG005","title":"Original CZP Dose - Weight Group: >=40 kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Pharmacokinetic Per-Protocol (PK-PP) Set was a subset of the SS consisting of those study participants who took at least 1 dose of study medication, provided measurable plasma CZP concentration samples (with recorded sampling date/time or for which date/time can be reasonably assumed). Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 16","title":"Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16","type":"PRIMARY","unitOfMeasure":"ug/ml"}